Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
Status:
Completed
Trial end date:
2018-05-11
Target enrollment:
Participant gender:
Summary
The overall goal of this imaging trial is to evaluate [18F]MNI-958, a tau targeted PET
radioligand, in individuals with Alzheimer's disease (AD), Progressive Supranuclear Palsy
(PSP), and healthy volunteers (HV).